Summary: Serum growth hormone levels were measured during insulin tolerance tests in 36 patients after yttrium-90 pituitary implantation for diabetic retinopathy.
Introduction
The beneficial effect of induced hypopituitarism on the progress of some aspects of diabetic retinopathy has been shown by a number of authors. The techniques used to reduce pituitary function include implantation of radioactive yttrium , transfrontal hypophysectomy (Luft, 1962; Ray et al., 1968) , transsphenoidal hypophysectomy , pituitary stalk section (Field et al., 1962) , and heavy particle irradiation (Linfoot, 1967) . The explanation of this beneficial effect is not known. Field (1965) suggested that near complete elimination of anterior pituitary function gave the best results. There have, however, been few reported studies on the effect of these procedures on individual pituitary functions and on the relation of the loss of particular functions to the response of the retinopathy. In one such study Powell et al. (1966) could find no relation between the loss of growth hormone secretion and the retinopathy response, whereas Teuscher et al. (1967) found a better response in those patients with low growth hormone levels.
In the series of patients treated at Hammersmith Hospital by pituitary implantation with yttrium-90 it was found that a definite endocrine deficit was usually followed by some improvement of retinopathy, while the best responses generally occurred in patients showing the most profound degrees of hypopituitarism . Growth hormone measurements were not considered in this previous analysis; however, the pituitary function of some of these patients has now been studied in more detail, both to look for a possible relation between retinopathy response and loss of growth hormone secretion, and also to correlate loss of growth hormone secretion with that of other pituitary endocrine functions. 
Methods

Patients Studied
Thirty-six patients with diabetic retinopathy were studied, on whom 40 pituitary implants with yttrium-90 had been performed between November 1960 and January 1968. The implants were planned to give three dose levels specified at the gland surface; this was 50,000 rads in seven patients, 150,000 rads in 30, and 300,000 rads in three. Four patients were reimplanted 5 to 13 months after an initial implant which had failed to induce hypopituitarism.
Diabetic control was maintained as tightly as feasible in each patient after operation. Those few patients referred for implantation in whom control was poor had an initial period during which the best possible control was imposed; implant was performed if the retinopathy remained severe enough to meet the criteria. Diabetic control was similar before and after implantation.
For the present study all available patients who fulfilled the following criteria were selected: (1) growth hormone secretory reserve had been measured three months or more after implant, using the stimulus of insulin-induced hypoglycaemia, in which adequate hypoglycaemia, defined as a venous blood sugar of less than 50 mg./100 ml. (Fraser and Wright, 1968) , had been achieved; (2) photographic assessment of the retinopathy had been made before implant and about one year later (range 3 to 27 months) ; and (3) before implantation at least one eye showed treatable retinopathy with visual acuity 6/24 (Snellen) or better, the macula was not threatened by fibrous retinitis proliferans, and visual symptoms were not principally due to hard exudates.
Ophthalmic Assessment
Detailed retinal assessments were made in 56 eyes. Each eye was assessed separately before and after the implant; thus after the 40 implants there was a possible total of 80 eyes for assessment. However, 24 eyes were excluded either because photographic assessment could not be made before implant or because our current assessment of photographs taken before implant showed that the retinopathy would not now be classified as treatable as defined above.
The individual features of the retinopathy were each graded into five grades of severity. This was done by comparing the colour photographs taken on a Zeiss retinal camera with a set of standard photographs of increasing severity of new vessels and retinal haemorrhages in each eye is shown in Fig. 1 
Discussion
The present study was undertaken to see whether there was any evidence that loss of growth hormone reserve was related to improvement in diabetic retinopathy after pituitary implantation. A better response, particularly of new vessels, was found when growth hormone reserve was maximally decreased. A similar response of new vessels has been shown in some of these patients by means of fluorescence photography ; only in patients in whom the pituitary had been completely ablated did some of the new vessel systems disappear. There is a suggestion that growth hormone can worsen diabetic retinopathy. Ray et al. (1968) reported that two patients in their series promptly developed fresh retinal haemorrhages when growth hormone was given during metabolic studies after hypophysectomy.
While our results showed that the best response of diabetic retinopathy followed elimination of growth hormone reserve, it was also shown that about 60% of eyes were either improved or held unchanged in patients whose peak growth hormone level was only slightly reduced. If these results are confirmed with more cases and a longer follow-up, a reduction of growth hormone would not appear to be essential for some response to pituitary implantation.
The present study showed that there was considerable difficulty in isolating the effect of reduction of any particular pituitary hormone, because all anterior pituitary functions tended to fall in parallel after implantation. Thus adrenal function was reduced as growth hormone reserve was reduced, and so a better retinopathy response was also found as adrenal function was progressively lost. However, decreased adrenal function is unlikely to account for the improvement in retinopathy. Adrenalectomy has only occasionally improved the condition (Graef and Maier, 1962 ; Malins, 1962) . Moreover, both Lourie et al. (1962) and Ray et al. (1968) have reported the case of a patient whose retinopathy was deteriorating after adrenalectomy but improved after hypophysectomy. In addition all patients in this present series undergoing complete pituitary ablation were maintained on corticosteroids.
It is possible that the mean daily growth hormone secretion was reduced in all the patients after implant, and that a reduction in the usual daily level of serum growth hormone was the dominant factor in retinopathy remission. Although growth hormone levels measured in response to insulin-induced hypoglycaemia may be the most appropriate test of the adequacy of pituitary ablation, they do not necessarily relate to the usual daily level. It may not be possible to determine the precise role of growth hormone in the improvement of retinopathy after pituitary ablation until such a daily secretion rate is measured.
